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Abstract
Background: Repeated exposure to a low dose of a bacterial endotoxin such as lipopolysaccharide (LPS) causes
immune cells to become refractory to a subsequent endotoxin challenge, a phenomenon known as endotoxin
tolerance (ET). During ET, there is an imbalance in pro- and anti-inflammatory cytokine and chemokine production,
leading to a dysregulated immune response. HIV-1 viral proteins are known to have an adverse effect on the
immune system. However, the effects of HIV-1 viral proteins during ET have not been investigated.
Methods: In this study, HIV-1 transgenic (HIV-1Tg) rats and control F344 rats (n = 12 ea) were randomly treated
with 2 non-pyrogenic doses of LPS (LL) to induce ET, or saline (SS), followed by a high challenge dose of LPS (LL
+L, SS+L) or saline (LL+S, SS+S). The gene expression of 84 cytokines, chemokines, and their receptors in the brain
and spleen was examined by relative quantitative PCR using a PCR array, and protein levels in the brain, spleen,
and serum of 7 of these 84 genes was determined using an electrochemiluminescent assay.
Results: In the spleen, there was an increase in key pro-inflammatory (IL1a, IL-1b, IFN-g) and anti-inflammatory (IL-
10) cytokines, and inflammatory chemokines (Ccl2, Ccl7, and Ccl9,) in response to LPS in the SS+L and LL+L (ET)
groups of both the HIV-1Tg and F344 rats, but was greater in the HIV-1Tg rats than in the F344. In the ET HIV-1Tg
and F344 (LL+L) rats in the spleen, the LPS-induced increase in pro-inflammatory cytokines was diminished and
that of the anti-inflammatory cytokine was enhanced compared to the SS+L group rats. In the brain, IL-1b, as well
as the Ccl2, Ccl3, and Ccl7 chemokines were increased to a greater extent in the HIV-1Tg rats compared to the
F344; whereas Cxcl1, Cxcl10, and Cxcl11 were increased to a greater extent in the F344 rats compared to the HIV-
1Tg rats in the LL+L and SS+L groups.
Conclusion: Our data indicate that the continuous presence of HIV-1 viral proteins can have tissue-dependent
effects on endotoxin-induced cytokine and chemokine expression in the ET state.
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Background
The bacterial endotoxin, lipopolysaccharide (LPS), is a
well-characterized glycolipid component of the cell wall
of gram-negative bacteria [1-3]. LPS is a model molecule
commonly used to study the inflammatory responses
caused by exposure to bacteria, in particular, the induc-
tion and actions of inflammatory cytokines and chemo-
kines [4-6]. An inflammatory response involves a
balance between the production of pro-inflammatory
cytokines and chemokines and the subsequent
production of anti-inflammatory cytokines [7]. An
imbalance in this mechanism can lead to disastrous
immune system-related consequences. Tight control of
pro-inflammatory cytokine production is necessary in
order to protect against septic shock. An imbalance in
this regulatory mechanism can also lead to the develop-
ment of endotoxin tolerance (ET) [8-14]. In ET,
repeated exposure to minute amounts of an endotoxin,
like LPS, causes immune cells, such as macrophages and
monocytes, to become refractory to a subsequent high-
dose endotoxin challenge [7,11,13,15-17]. On re-expo-
sure to an endotoxin, when the animal is in an ET state,
there is an increase in production of anti-inflammatory
cytokines and a decrease in production of pro-
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sure to the endotoxin [14]. ET is known to resemble
immunosuppression in many aspects reported in
patients with sepsis or non-infectious systemic inflam-
matory response syndrome (SIRS) [18]. While ET initi-
ally protects against severe infection and tissue damage
by overt inflammatory response, however the immune
dysregulation observed in ET and in SIRS patients is
associated with greater propensity to succumb to noso-
comial infections [18,19].
The Human immunodeficiency virus-1 (HIV-1) is
characterized by very rapid viral replication. The virus is
subsequently transported to the lymphoid organs and
the central nervous system (CNS). A very strong cellular
and humoral immune response is evoked in the host
within a few weeks [20], after which there is a clinical
latency period, sometimes for years, followed by rapid
clinical deterioration [21]. It is believed that the contin-
ued presence of HIV-1 viral proteins plays a role in the
clinical progression of HIV-1 infection to full-blown
AIDS [22-26].
Since 1996, highly active anti-retroviral therapy
(HAART) has resulted in a dramatic improvement in
the health and longevity of HIV-infected individuals
[27]. However, HAART drugs are limited in their capa-
city to enter the CNS and other organs that are pro-
tected by tight endothelial barriers. Thus, in this post-
HAART era, the clinical challenge is to identify the bio-
logical and physiological changes that occur due to the
persistent presence of HIV-1 viral proteins in the host
even when active viral replication is arrested [28,29].
Some HIV-1 viral proteins have been shown to affect
the inflammatory response by altering the production of
cytokines. For example, the HIV-1 Tat protein can alter
the LPS-induced production of IFN-b and IL-6 in blood
monocytes/macrophages [30], and HIV-1 Vpr sup-
presses IL-12 production in human monocytes [31].
However, the effects of HIV-1 viral proteins on immune
function during a state of ET has not been examined.
The HIV-1 transgenic (HIV-1Tg) rat model was devel-
oped with a functional deletion of the gag and pol genes
in the HIV-1 genome. It is, however, under the control
of the viral promoter and expresses seven of the nine
H I Vg e n e s[ 3 2 ] .T h u s ,i nt h eH I V - 1 T gr a t ,t h e r ei sn o
HIV-1 replication, but other HIV-1 viral proteins are
expressed [32]. We have shown that, like HIV-1 infected
patients, the HIV-1Tg rat is immunodeficient. LPS-
induced leukocyte-endothelial adhesion (LEA) is greatly
attenuated in the HIV-1Tg rat [33]. In addition, the
HIV-1Tg rat shows signs of wasting and dies at a
younger age even though there is no growth retardation
and no sign of anorexia throughout its life span [34].
These rats also have decreased alveolar macrophage zinc
levels and phagocytosis [35]. The HIV-1Tg rat model,
thus, exhibits some of the characteristics of HIV-1
infected patients given HAART [36-39].
There is an association between chronic HIV infection
and elevated plasma endotoxin levels. Innate immune
responses, which are dysregulated in ET, are also altered
in HIV infection [40]. The cytokines/chemokines modu-
lated during ET play a role in HIV infection, replication
(not applicable for our model) and pathogenesis. Toll-
like receptor 4 (TLR4) mediates gram-negative bacteria
activated signaling and significant changes in this recep-
tor’s level is directly correlated with HIV infection [41].
TNF-a upregulation leads to HIV-induced cytotoxicity
[42]. Enhanced levels of Ccl2 in HIV-1 patients have
been associated with HIV-1-associated dementia [43].
The Center for Disease Control (CDC) has identified
HIV-1 infection as a major reason for the increase in
incidence of sepsis [44]. Opportunistic infections are a
common feature in HIV-1 positive patients, who have a
compromised immune status [45]. ET leads to a similar
immunosuppressed state. Identifying the mechanism by
which ET affects an already immune-compromised sys-
tem, as in HIV-1 infection, could provide valuable infor-
mation of clinical relevance. We hypothesized that the
continuous presence of HIV-1 viral proteins alters the
systemic immune response to bacterial endotoxins in
terms of pro- and anti-inflammatory cytokine and che-
mokine expression, and that this altered immune
response is exacerbated when the animal is in an ET
state. Specifically, we hypothesized that the production
of pro-inflammatory cytokines is diminished and anti-
inflammatory cytokine production is enhanced in the
HIV-1Tg rat rendered endotoxin tolerant. To test this
hypothesis, in this study, we examined the expression of
an array of cytokines, chemokines, and their receptors
in the serum, spleen, and brain of an endotoxin tolerant
HIV-1Tg rat model in response to an LPS challenge.
Methods
Animals
Adolescent male Sprague-Dawley HIV-1 transgenic
(HIV -1Tg) rats and age-matched Fisher/NHsd 344
(F344) control rats were purchased from Harlan Labora-
tories (Indianapolis, IN), and were delivered on post-
natal day 28. The animals were group-housed immedi-
ately upon arrival, and stayed in group cages during the
experiment. The animals were maintained in an envir-
onment of controlled temperature (21-22°C) on a 12-h
light/12-h dark illumination cycle, with lights-on set at
7:00 AM. Food and tap water were provided ad libitum.
The experimental protocol was approved by the Institu-
tional Animal Care and Use Committee (IACUC) at
Seton Hall University, South Orange, NJ.
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Dosing solutions of LPS were prepared in saline. In our
preliminary studies using Harlan Sprague Dawley rats,
we found that two intraperitoneal (i.p) injections with a
non-pyrogenic dose (250 μg/kg ea) of LPS, administered
9-12 hrs apart, was the lowest dosage regimen that
would cause endotoxin tolerance and inhibit the pro-
duction of IL-1b, TNF-a, and IL-6 in response to a sub-
sequent challenge with a significantly higher dosage of
LPS [1, 4, 8, 16, or 32 mg/kg] (data not shown). In this
study, HIV-1Tg and F344 rats (n = 12 ea, 19-20 wks
old) were randomly assigned to four experimental
groups (n = 3 animals/group). At 8:00 AM and 5:00 PM
on Day 1, Groups 1 and 2 received two i.p. injections of
250 μg/kg LPS each (LL); Groups 3 and 4 received two
i.p. injections of saline (SS). At 8:00 AM on Day 2,
Group 1 received one i.p. injection with 5 mg/kg LPS
(LL+L); Group 2 received one i.p. injection with saline
(LL+S); Group 3 received one i.p. injection with 5 mg/
kg LPS (SS+L); and Group 4 received one i.p. injection
with saline (SS+S). The dosage of 5 mg/kg for the sub-
sequent LPS injection was chosen based on previous
studies using the HIV-1Tg rat model [46]. Two hours
following the last injection, the brains, spleens, and
blood were collected for RNA, protein, and serum
preparation.
Protein extraction from the brain and spleen
Protein extracts were prepared from approximately 100
mg of brain and spleen tissue in a Tris lysis buffer con-
t a i n i n g2 0m MT r i s ,p H7 . 5 ,1m ME D T A ,1m M
EGTA, and 1 M NaF (all from Sigma Aldrich, St. Louis,
MO), and 1 tablet of Protease Inhibitor (Roche, Man-
nheim, Germany). The tissues were disrupted using the
Branson Sonifier 250 (VWR, Radnor, PA) with 15 sec
bursts, a duty cycle setting of 40% (0.4 sec burst/0.6 sec
pause), and an output of 4. The concentration of protein
from each of the tissue types was determined using the
ProStain assay kit (Active Motif, Carlsbad, CA), and
measured as fluorescence intensity against a BSA stan-
dard curve with the Spectra Max Gemini (Molecular
Devices, Sunnyvale, CA).
Measurement of inflammatory cytokines
Protein levels of IL-1b, KC/GRO, IL-4, IL-5, TNF-a, IFN-
g, and IL-13 were determined in undiluted serum and in
extracts from 200 μg of brain and spleen using a 96-well
inflammatory cytokine kit [MesoScale Discovery (MSD),
Gaithersberg, MD]. Measurement of electrochemilumi-
nescent signal intensity was determined on the SECTOR
2400 instrument (MesoScale Discovery, Gaithersberg,
MD). Calibrator solutions were diluted 4-fold over a con-
centration range of 40,000 pg/mL to 9.8 pg/mL.
RNA isolation and preparation of cDNA
Total RNA was extracted from brain and spleen homo-
genates using TRIZOL (Invitrogen, Carlsbad, CA). The
extracts were then treated with Ambion
® TURBO
DNA-free™ (Ambion, Austin, TX) to remove contami-
nating DNA, and harvested using a RNeasy mini kit
(Qiagen, Valencia, CA). RNA quality and quantity were
assessed using a Nanodrop spectrophotometer. Equal
amounts of RNA from each sample were then converted
into first-strand cDNA using a RT2 First Strand Kit (SA
Biosciences, Frederick, MD),
Real-time PCR array
Detection and quantification of gene expression were
performed using a Rat Inflammatory Cytokines and
Receptors PCR Array and RT
2 SYBR Green Fluorescin
qPCR Master (SA Biosciences, Frederick, MD) accord-
ing to the manufacturer’si n s t r u c t i o n s .T h i sk i tw a s
chosen because it includes diverse genes important in
immune responses, including genes encoding CC che-
mokines (n = 16), CXC chemokines (n = 9), interleu-
kin cytokines (n = 14), other cytokines (n = 11),
chemokine receptors (n = 15), and cytokine receptors
( n=1 1 ) ,a sw e l la so t h e rg e n e si n v o l v e di nt h ei n f l a m -
matory response (n = 8).
Real-time PCR was performed using an ABI Prism
7900HT Fast Detection System (Applied Biosystems,
Foster, CA). Each 10 μLr e a c t i o nw a sp e r f o r m e di na
384-well format PCR array. The PCR mix was denatured
at 95°C for 10 min before the first PCR cycle. The ther-
mocycler parameters were 95°C for 10 min, followed by
40 cycles at 95°C for 15 s, and 60°C for 1 min.
PCR array data analysis
In order to be able to compare different PCR array
results, the threshold and baseline values were set
manually, according to the manufacturer’si n s t r u c t i o n s ,
and the resulting threshold cycle value (CT) data were
uploaded into the data analysis template on the manu-
facturer’s website http://www.sabiosciences.com/pcr/
arrayanalysis.php. RNA expression of each gene was
normalized using five housekeeping genes as controls.
The relative expression of each gene, compared with the
expression in the control group, was calculated on the
website using the ΔΔCT method. A difference was con-
sidered significant at p < 0.05. In the expression studies,
a gene was considered differentially regulated if the dif-
ference was > 2-fold compared with the control, and
markedly differentially regulated if the difference was >
10-fold [47-52]. Each reported value represents the
mean increase or decrease of mRNA expression relative
to the levels for the controls from three biological
replicates.
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Inflammatory cytokine protein level data in this study
are presented as the mean ± SD. Statistical analysis was
done using Graphpad Prism 5.0. Differences among
treatment groups were analyzed by a one-way ANOVA,
followed by a Newman-Keuls post hoc test. The differ-
ence in the basal levels of cytokines/chemokines in the
brain, spleen, and serum between F344 and HIV-1Tg
rats was determined using the Student’st -test.
Results
Cytokine and chemokine protein expression in the serum,
brain, and spleen of HIV-1Tg rats during endotoxin
tolerance (ET)
The protein levels of IL-1b,K C / G R O ,I L - 4 ,I L - 5 ,T N F -
a,I F N - g, and IL-13 were determined in the brain,
spleen, and sera of HIV-1Tg and F344 rats rendered ET
(LL), then challenged with either LPS (LL+L) or saline
(LL+S), using an electrochemiluminescent (MSD) assay
(Table 1, 2, 3). Saline-treated animals were used as con-
trols (SS+S). There was no difference in the basal levels
(SS+S group levels) of the cytokines/chemokines mea-
sured in the serum in the two strains of animals (Table
1). In the F344 serum, the levels of the pro-inflamma-
tory cytokine, IFN-g, and the anti-inflammatory cyto-
kines, IL-4 and IL-13, in the single exposure group (SS
+L) were significantly greater than in the control group
(SS+S), and significantly less in the ET group (LL+L)
than in the single exposure group (SS+L). In the HIV-
1Tg serum, the levels of the pro-inflammatory cytokines,
IL-1b,T N F - a,a n dI F N - g, and the anti-inflammatory
cytokines, IL-4 and IL-13, in the single exposure group
(SS+L) were significantly higher than in the control
group (SS+S), and significantly lower in the ET group
(LL+L) than in the single exposure group (SS+L) [Table
1].
The basal levels of IL-4 and TNF-a in the F344 rat
brain, and IL-4, IL-5, and TNF-a in the HIV-1Tg brain,
were not detectable by electrochemiluminescent (MSD)
assay. The basal levels of cytokines/chemokines that
were detectable in the brain were similar in both strains
of animals (Table 2). An LPS challenge dose (SS+L and
LL+L) did not significantly alter any of the cytokine/
chemokine levels in the F344 rat brain (Table 2). How-
ever, in the HIV-1Tg rat brain, the levels of the pro-
inflammatory cytokines, IL-1b and IFN-g,w e r es i g n i f i -
cantly higher in the SS+L group versus the control. The
level of the pro-inflammatory cytokine, IFN-g,w a ss i g -
nificantly lower in the LL+L group compared to the SS
+L group (Table 2).
The basal level of TNF-a was not detectable in the
spleen of either the F344 or HIV-1Tg rats (Table 3).
There was no significant difference in the basal levels of
any of the cytokines/chemokines that were detectable in
the spleen of the F344 and HIV-1Tg rats, with the
exception of IFN-g, which was significantly greater in
the F344 rat spleen compared to that in the HIV-1Tg
rat spleen (Table 3). In the F344 spleen, the levels of the
pro-inflammatory cytokines, IL-1b and IFN-g,a n dt h e
anti-inflammatory cytokines, IL-4 and IL-13, in the
Table 1 Cytokine/Chemokine Profiles in F344 and HIV-1Tg Rat Serum
Cytokines and Chemokines in the Serum with LPS Treatment
Protein (pg/ml, ± SD)
F344 IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1
beta
Interleukin 4 Interleukin 5 Tumor necrosis factor -
alpha
Interferon
gamma
Interleukin
13
SS+S 83.0(± 21.3) 1294.8(± 589.7) 9.5(± 0.6) 116.0(± 23.7) 42.7(± 6.1) 35.2(± 7.2) 27.5(± 1.1)
SS+L 272.1(± 145.1) 7153.2(± 2779.8)** 15.5(± 1.7)
***
348.7(±
202.4)
7531.8(± 7897.0) 138.6(± 46.2)** 42.3(± 9.5)
**
LL+S 80.4(± 42.4) 780.9(± 846.6) 10.3(± 51.2) 103.6(± 32.6) 51.2(± 12.4) 56.5(± 19.6) 22.5(± 1.1)
LL+L 125.1(± 23.5) 3293.5(± 680.6)* 11.1(± 1.1)
^^
210.0(± 56.7) 88.2(± 25.5) 61.8(± 18.9)^^ 26.5(± 2.1)^
HIV -
1Tg
IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1
beta
Interleukin 4 Interleukin 5 Tumor necrosis factor -
alpha
Interferon
gamma
Interleukin
13
SS+S 85.2(± 31.6) 1907.4(± 978.9) 10.7(± 2.0) 154.7(± 83.6) 45.2(± 11.4) 67.8(± 32.2) 26.8(± 0.5)
SS+L 307.4(± 72.9)
***
7002.2(± 361.0)*** 14.4(± 2.5) 258.3(± 37.3) 2366.7(± 924.4)*** 122.3(± 13.4)* 36.2(± 6.6)*
LL+S 47.9(± 7.4) 327.6(± 110.5) 8.0(± 1.4) 29.7(± 34.3) 42.8(± 7.0) 18.3(± 24.9) 22.3(± 1.1)
LL+L 128.6(± 3.0)^^^ 3051.3(± 1215.7)
^^^
11.3(± 0.8)
^^
189.1(±
121.1)
113.4(± 51.8)^^^ 71.1(± 9.1)^ 27.9(± 4.2)^
* P < 0.05, ** P < 0.01, *** P < 0.001 greater than SS+S control; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 less than SS+L; statistically significant changes are bolded
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than in the control. In the F344 rats, the levels of the
pro-inflammatory cytokines, IL-1b and IFN-g,a n dt h e
anti-inflammatory cytokine, IL-4, were significantly
lower in the spleen of the LL+L group compared to the
single exposure group (SS+L). In the HIV-1Tg spleen,
the levels of the pro-inflammatory cytokines, IL-1b and
IFN-g, and the anti-inflammatory cytokine, IL-4, were
significantly higher in the single exposure group (SS+L)
and in the endotoxin tolerant group (LL+L) compared
to the control. In the LL+L group of HIV-1Tg rats, the
pro-inflammatory cytokines, IL-1b and IFN-g,a n dt h e
anti-inflammatory cytokine, IL-4, were significantly
lower than in the single exposure (SS+L) group (Table
3).
Expression profiles of cytokines, cytokine-receptors, and
other inflammatory molecules in the brain and spleen of
the HIV-1Tg rat following LPS treatment
The gene expression profiles of an array of cytokines,
cytokine receptors, and other inflammatory molecules
were determined in the brain and spleen of the three
Table 2 Cytokine/Chemokine Profiles in the F344 and HIV-1Tg Rat Brain
Cytokines and Chemokines in the Brain with LPS Treatment
Protein (pg/ml, ± SD)
F344 IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1 beta Interleukin 4 Interleukin 5 Tumor necrosis factor - alpha Interferon gamma Interleukin 13
SS+S 42.2(± 8.8) 74.4(± 23.3) ND 56.5(±) ND 15.3(± 7.5) 4.4(± 1.8)
SS+L 178.4(± 162.1) 1325.3(± 1431.3) 13.5() 102.8(± 61.1) 30.9 20.5(± 11.9) 4.8(± 3.1)
LL+S 59.1(± 26.3) 112.6(± 35.6) 3.4 74.7 ND 14.7(± 7.0) 6.9(± 1.4)
LL+L 207.0(± 133.0) 1036.2(± 685.6) 2.9(± 1.3) 141.9(± 98.3) ND 21.9(± 6.5) 5.3(± 2.3)
HIV - 1Tg IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1 beta Interleukin 4 Interleukin 5 Tumor necrosis factor - alpha Interferon gamma Interleukin 13
SS+S 37.3(± 17.1) 125.3(± 87.8) ND ND ND 11.7(± 5.2) 5.1(± 0.4)
SS+L 361.7(± 104.6)* 2991.3(± 491.5)** 9.2(± 3.1) 164.2(± 35.3) 109.5 47.1(± 14.5)* 9.3(± 4.2)
LL+S 56.5(± 15.1) 128.1(± 61.6) ND ND ND 8.9(± 5.9) 4.6(± 1.4)
LL+L 208.6(± 167.4) 1312.9(± 1039.2)^ 8.1(± 1.6) 181.2(± 50.0) 27.3 24.3(± 14.5)^ 7.3(± 3.7)
* P < 0.05, ** P < 0.01, *** P < 0.001 greater SS+S control; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 less than SS+L; statistically significant changes are bolded
Table 3 Cytokine/Chemokine Profiles in the F344 and HIV-1Tg Rat Spleen
Cytokines and Chemokines in the Spleen with LPS Treatment
Protein (pg/ml, ± SD)
F344 IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1 beta Interleukin 4 Interleukin 5 Tumor necrosis factor -
alpha
Interferon
gamma
Interleukin
13
SS+S 1802.9(± 635.7) 264.7(± 122.7) 6.9(± 3.3) 119.5(± 20.0) ND 34.5(± 13.6) 3.7(± 2.3)
SS+L 19030.7(±
11365.4)*
20065.6(± 11858.1) 50.7(± 16.0)
**
344.4(± 83.9)
**
2943.6(± 2752.3) 203.3(± 71.5)** 22.1(± 6.0)
**
LL+S 3325.3(± 440.6) 506.6(± 205.0) 6.8(± 5.7) 120.0(± 28.8) ND 32.5(± 28.1) 3.8(± 3.0)
LL+L 7898(± 1996.9)^ 11818.7(± 9648.2) 21.6(± 10.2)
^^
246.6(± 79.4) 228.7(± 19.6) 105.3(± 45.0)*^ 14.2(± 6.1)
HIV -
1Tg
IL-1b KC/GRO IL-4 IL-5 TNF-a IFN-g IL-13
Interleukin 1 beta Interleukin 4 Interleukin 5 Tumor necrosis factor - a Interferon
gamma
Interleukin
13
SS+S 1274.5(± 122.3) 361.1(± 187.7) 3.8(± 1.4) 107.7(± 33.0) ND 10.8(± 4.8) 0.8(± 0.7)
SS+L 19951.8(± 4023.8)
**
25812.5(± 3014.5)
**
41.8(± 5.7)** 395.4(± 93.3)
**
2755.4(± 1596.0) 296.9(± 83.4)** 32.0(± 4.9)*
LL+S 5087.1(± 1675.4) 961.8(± 89.1) 7.3(± 2.0) 178.4(± 57.2) ND 19.8(± 2.6) 6.6(± 6.4)
LL+L 11443.1(± 7400)*^ 12754.4(±
11613.3)^
27.3(± 12.6)
*^
239.4(± 77.1)
^
356.7(± 149.4) 151.5(± 77.6)*^ 19.8(± 11.4)
* P < 0.05, ** P < 0.01, *** P < 0.001 greater than SS+S control; ^ P < 0.05, ^^ P < 0.01, ^^^ P < 0.001 less than SS+L; statistically significant changes are bolded
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compared to the control group (SS+S) of both the HIV-
1Tg and F344 rats (Figure 1). In the F344 and HIV-1Tg
rat brain, the level of the pro-inflammatory cytokine, IL-
1b, was elevated in the LL+L (> 9 fold) and SS+L (> 4
fold) groups. The level of the anti-inflammatory cyto-
kine, IL-10, was elevated in the brain of both the SS+L
(> 3 fold) and LL+L (> 2 fold) groups in the F344 rats,

Fold Regulation Compared to Control (SS+S) 
Gene 
Brain Spleen 
F344     HIV-1 Tg  F344     HIV-1 Tg 
SS+L LL+S LL+L    SS+L LL+S LL+L    SS+L LL+S LL+L    SS+L LL+S LL+L 
Interleukins (n=14) 
Il1a  Interleukin 1 alpha                          46.0 2.7 25.9     56.8 2.0 32.3
Il1b  Interleukin 1 beta  4.4 3.6 9.2     6.0 2.5 9.5     13.5     5.7     41.1 2.6 19.9
Il3  Interleukin 3        2.0           2.2        -5.0        2.6 -3.4    
Il4 Interleukin  4  -2.7              2.3           -7.3  -3.2           -2.0 
Il5  Interleukin 5                             -2.8                
Il1f5  Interleukin 1 family, member 5 (delta)              -2.7  -2.0           -2.8  -3.9     -19.9  -12.0 
-
23.5
Il1f6  Interleukin 1 family, member 6              -3.0  -2.5  -2.4        -6.4  -6.1  -3.2  -3.1    
Il10 Interleukin  10  3.2     2.2     2.2           7.4     8.3     23.8 2.0 12.7
Il11  Interleukin 11                          -2.1           -2.5  -6.0 
Il13  Interleukin 13                                      -3.1  -3.0  -4.5 
Il15  Interleukin 15                          3.4           2.5 -3.0  -2.7 
Il16  Interleukin 16                          -2.1     -2.5     -7.6  -2.1  -6.0 
Il17b  Interleukin 17B                                         -2.9  -7.3 
Il18  Interleukin 18                                              
Other Cytokines (n=11) 
Ifng  Interferon gamma                          84.5          165.7  -4.9    
Itgam  Integrin alpha M                 4.0                            
Itgb2  Integrin beta 2                 2.1              -2.5             
Lta  Lymphotoxin alpha (TNF superfamily, member 1)        2.3                 3.2           3.6       
Ltb  Lymphotoxin beta (TNF superfamily, member 3)                                              
Mif  Macrophage migration inhibitory factor                                              
Scye1  Small inducible cytokine subfamily E, member 1                                              
Spp1  Secreted phosphoprotein 1                          -3.1     2.2     -2.5  -2.8    
Tgfb1  Transforming growth factor, beta 1                                -2.9             
Tnf  Tumor necrosis factor (TNF superfamily, member 2)                          23.6     3.5     6.6       
Cd40lg  CD40 ligand                                -2.6           -2.2 
Cytokine receptors (n=11) 
Il1r1  Interleukin 1 receptor, type I                          3.9     2.8     4.0     4.0
Il1r2  Interleukin 1 receptor, type II                 3.5        2.5 4.3 2.7     5.8 11.0 7.5
Il2rb  Interleukin 2 receptor, beta              2.0 2.0                            
Il2rg  Interleukin 2 receptor, gamma  2.1           4.1 2.5 2.5                         
Il5ra  Interleukin 5 receptor, alpha              -3.0  -3.3                       -2.9  -2.7 
Il6ra  Interleukin 6 receptor, alpha              2.8                 -2.6             
Il10ra  Interleukin 10 receptor, alpha                                -2.0             
Il13ra1  Interleukin 13 receptor, alpha 1                 2.2                          2.1
Il6st  Interleukin 6 signal transducer                   
-
12.2                2.1       
Tnfrsf1a  Tumor necrosis factor receptor superfamily, member 1a                                              
Tnfrsf1b  Tumor necrosis factor receptor superfamily, member 1b                                -2.2     2.8       
Other Inflammatory molecules (n=7) 
Abcf1  ATP-binding cassette, sub-family F (GCN20), member 1                                              
Bcl6  B-cell CLL/lymphoma 6        2.0     2.6              -2.4  -2.6     2.1       
C3  Complement component 3        2.2        6.7           2.2 2.4        2.0 2.2
Casp1  Caspase 1                                              
Crp  C-reactive protein, pentraxin-related              -2.4  -4.1  -2.6     2.8 -2.8        -10.1  -3.9 
RGD156190
5_predicted  Complement component 5              -3.7  -3.2  -2.8     2.0           -4.6     -6.6 
Tollip  Toll interacting protein                                -2.2             
   < 2 fold increase/decrease 
   2-5 fold increase 
   6-20 fold increase 
   21-50 fold increase 
51-100 fold increase 
100+ fold increase 
   2 to 5 fold decrease  
6 to 20 fold decrease  
Figure 1 Cytokine Expression in the Brain and Spleen of F344 and HIV-1Tg Rats.
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Page 6 of 11but only in the brain of the SS+L (> 2 fold) group in the
HIV-1Tg rat brain (Figure 1). In the spleen of the F344
and HIV-1Tg rats, the levels of the pro-inflammatory
cytokines, IL-1a,I L - 1 b,w e r ee l e v a t e di nb o t ht h eS S + L
(> 10 fold) and LL+L (> 5 fold) groups. The levels of
the pro-inflammatory cytokines, IFN-g and TNF-a, were
increased in the SS+L group (> 6 fold), and the anti-
inflammatory cytokine, IL-10, was higher in the SS+L (>
5 fold) and LL+L (> 7 fold) groups (Figure 1).
Expression profiles of chemokine and chemokine receptors
in the brain and spleen of the HIV-1Tg rat following LPS
treatment
The gene expression profiles of various chemokines and
chemokine receptors were examined in the three LPS
treatment groups and compared to the control group
(SS+S) in both the HIV-1Tg and F344 rats (Figure 2).
The gene expression of the inflammatory cc chemo-
kines, Ccl2, Ccl3, Ccl7, and Ccl20, and inflammatory
Cxc chemokines, Cxcl1, Cxcl2, and Cxcl10, were up-
regulated in the brain and spleen in the SS+L and LL+L
groups of both the F344 and HIV-1Tg rats. The gene
expression of the inflammatory cc chemokines, Ccl11
and Ccl24, were down-regulated in the brain of the LL
+L group of both the F344 and HIV-1Tg rats, and in
the SS+L and LL+L groups in the spleen of the HIV-
1Tg rats.
Ten of the 15 (10/15) chemokine receptors studied were
down-regulated in the LL+L group of the spleen of the
F344 rats. One of 15 (1/15) and three of 15 (3/15) che-
mokine receptors were down-regulated in the LL+L
g r o u po ft h eb r a i no ft h eF 3 4 4a n dH I V - 1 T gr a t s ,
respectively; ten of 15 (10/15) and two of 15 (2/15) che-
mokine receptors were diminished in the LL+L group of
the spleen of the F344 and HIV-1Tg rats (Figure 2).
Discussion
Endotoxin tolerance (ET) is a phenomenon in which
previous exposure of cells or organisms to microbial
products, such as the endotoxin, LPS, induces a transi-
ent period of hypo-responsiveness to a subsequent
endotoxin challenge. Exposure to an endotoxin initi-
ates the production of pro-inflammatory cytokines and
a subsequent production of anti-inflammatory cyto-
kines by immune cells [7,15,53,54]. ET is characterized
by diminished release of pro-inflammatory cytokines,
such as IL-1b,I L - 1 a,a n dT N F - a,a n di n c r e a s e d
expression of anti-inflammatory cytokines, such as 1L-
10 [14]. This negative feedback mechanism is impor-
tant for protecting the host from tissue damage and
death caused by excessive inflammation The differen-
tial expression of cytokines/chemokines in different tis-
sues and at different times has been examined in
Sprague Dawley rats to investigate the modulation of
immune responses [46].
The occurrence of ET has been shown to increase the
incidence of several diseases, including sepsis, pancreati-
tis, trauma and surgery [55]. The CDC has identified the
increase of HIV-1 positive population as a major factor
in the increased incidence of sepsis [44]. Studies have
shown that the presence of HIV viral proteins causes a
compromised immune response in HIV-1 patients
[56-60]. The phenomenon of ET during HIV-1 infection
has not been studied through animal models. Reid and
colleagues [32] established a non-infectious HIV-1 trans-
genic (HIV-1Tg) rat model that expresses an HIV-1 pro-
virus regulated by the viral promoter, but with a
functional deletion of gag and pol. The characteristics of
the HIV-1Tg rat include immunologic dysfunction,
nephropathy, muscle wasting, skin lesions, and cataracts.
We studied the systemic effect of the concurrent pre-
sence HIV-1 viral proteins and ET on the inflammatory
response to bacterial endotoxin using the HIV-1Tg rat
model. We examined the LPS-induced gene expression
of 84 cytokines, chemokines, and their receptors in the
blood, brain, and spleen of the endotoxin tolerant HIV-
1Tg rat. Based on previous studies, we used two injec-
tions of a low dose of LPS (250 μg/kg) administered 9 h
apart to induce ET, and a challenge injection with a
high dose of LPS (5 mg/kg) 12 h later. A single expo-
s u r et oah i g hd o s eo fe n d o t o x i ns h o u l dc a u s eas i g n i f i -
cant increase in the levels of pro-inflammatory and anti-
inflammatory cytokines compared to control [46]. In the
ET state, when animals are exposed to repeated low
doses of endotoxin, upon a subsequent challenge with a
high dose of the endotoxin, one would expect that the
increase in the pro-inflammatory cytokine levels would
be lower compared to that in the single high dose expo-
sure group [14]. To confirm that the animals were in
the ET state, we measured the protein levels of inflam-
matory cytokines after the LPS challenge dose. Although
the basal levels in the brain, spleen, and serum of the
control groups (SS+S) of F344 and HIV-1Tg rats were
similar, the changes in the cytokine and chemokine pro-
files in response to LPS were different in the HIV-1Tg
and F344 rats. We found that, during ET, there was a
significantly diminished expression of pro-inflammatory
cytokines, such as IL-1b, IFN-g, and TNF-a, in response
to LPS (LL+L) compared to a single exposure of LPS
(SS+L).
Of particular interest was the finding that the basal
level of IFN-g in the spleen was lower in the SS+S
group of HIV-1Tg rats than of the F344 rats, but was
significantly increased in the SS+L and LL+L groups of
the HIV-1Tg rats compared to the F344 rats (Table 3).
A recent study showed that IFN-g countered ET by
facilitating Toll-like receptor (TLR)-induced chromatin
remodeling [61]. ET was prevented in IFN-g pre-treated
primary human monocytes, and production of pro-
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Page 7 of 11inflammatory cytokines, such as TNF-a and IL-6, was
restored by facilitating TLR-induced chromatin remodel-
ing [61]. It would be interesting to examine what role
IFN-g plays in the restoration of the production of pro-
inflammatory cytokines at the transcriptional level in
the HIV-1Tg rat compared to control.
We found that, in both the ET state and after a single
exposure to LPS, there was an altered response to LPS
Fold Regulation Compared to Control (SS+S) 
Gene 
Brain Spleen
F344     HIV-1 Tg  F344     HIV-1 Tg 
SS+L LL+S LL+L    SS+L LL+S LL+L    SS+L LL+S LL+L    SS+L LL+S LL+L 
C-C motif Chemokines (n=16) 
Ccl2  Chemokine (C-C motif) ligand 2  2.0     3.7     5.0     6.7     94.7 42.6     90.6 82.0
Ccl3  Chemokine (C-C motif) ligand 3  2.7 3.6 5.2     5.0 3.4 7.9     14.3     4.1     13.1     2.6
Ccl4  Chemokine (C-C motif) ligand 4        4.9     7.4 4.4 7.3     14.4           26.6       
Ccl5  Chemokine (C-C motif) ligand 5                    -2.5                 3.9     2.4
Ccl6  Chemokine (C-C motif) ligand 6  -2.0              2.5 2.2                         
Ccl7  Chemokine (C-C motif) ligand 7  3.0     3.8     7.3 3.1 9.6     12.6     10.0     24.0     17.7
Ccl9  Chemokine (C-C motif) ligand 9        2.0                 9.5     7.2     32.3 4.2 33.0
Ccl11  Chemokine (C-C motif) ligand 11        -2.5           -6.9        -6.4        -2.4  -3.7  -3.7 
Ccl12  Chemokine (C-C motif) ligand 12     3.1 3.4     2.6 4.6 3.6     22.3     3.7     8.3     2.6
Ccl17  Chemokine (C-C motif) ligand 17                             -2.1           -2.4    
Ccl19  Chemokine (C-C motif) ligand 19                                              
Ccl20  Chemokine (C-C motif) ligand 20  3.5 6.7 24.2     10.5 9.9 17.5    155.7  65.0 74.0 46.2
Ccl21b  Chemokine (C-C motif) ligand 21b (serine)                                -2.7        -3.0  -4.6 
Ccl22  Chemokine (C-C motif) ligand 22  2.0                       2.8           7.4       
Ccl24  Chemokine (C-C motif) ligand 24     -2.6  -4.7     -2.5  -2.1  -2.4           -2.3     -2.1  -2.8  -3.2 
Ccl25  Chemokine (C-C motif) ligand 25                          -3.0           -3.3     -3.5 
C-X-C motif Chemokines (n=9) 
Cxcl1
Chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating activity, 
alpha)  54.1 26.3     17.4     13.3    127.7  47.8     39.9     11.1
Cxcl2  Chemokine (C-X-C motif) ligand 2  10.9 2.4 11.8     10.8     13.0    290.4  85.6 154.4  40.7
Cxcl6
Chemokine (C-X-C motif) ligand 6 
(granulocyte chemotactic protein 2)        2.0           -3.3     7.3     5.9     8.6     11.1
Cxcl9  Chemokine (C-X-C motif) ligand 9  3.2 -4.6  -2.8     9.5           2.0           7.9       
Cxcl4
(Pf4)  Platelet factor 4        -2.1                                     
Cxcl10  Chemokine (C-X-C motif) ligand 10  59.2 4.6     29.2 3.0 2.8     35.0           81.6 2.3
Cxcl11  Chemokine (C-X-C motif) ligand 11  71.8 2.1 14.1     29.3     4.9     6.2     -2.0     19.0       
Cxcl12 
Chemokine (C-X-C motif) ligand 12 
(stromal cell-derived factor 1)                                -2.4             
Cx3cl1  Chemokine (C-X3-C motif) ligand 1                          2.8 -3.3           -10.5 
Chemokine Receptors (n=15) 
Ccr1  Chemokine (C-C motif) receptor 1              -3.1              2.2        2.9 4.4 5.1
Ccr2  Chemokine (C-C motif) receptor 2     2.1              2.5           -2.0             
Ccr3  Chemokine (C-C motif) receptor 3              2.4                 -2.2        -2.4    
Ccr4  Chemokine (C-C motif) receptor 4                             -2.4  -4.7     2.3       
Ccr5  Chemokine (C-C motif) receptor 5                                -2.0     2.3       
Ccr6  Chemokine (C-C motif) receptor 6  -2.5           -11.2  -4.7  -2.7                 2.3     3.9
Ccr7  Chemokine (C-C motif) receptor 7     2.9           5.3 2.6        -2.1  -3.5             
Ccr8  Chemokine (C-C motif) receptor 8              -2.0  -2.8           -2.7                
Ccr9  Chemokine (C-C motif) receptor 9  2.9 2.2                                        
Cxcr3  Chemokine (C-X-C motif) receptor 3                          -2.6  -2.1  -3.8             
Ccr10  Chemokine (C-C motif) receptor 10                                -2.7             
Cx3cr1  Chemokine (C-X3-C motif) receptor 1                          -2.3  -3.2  -6.5        -2.1    
Il8ra  Interleukin 8 receptor, alpha  -2.2  -3.7        2.8              -2.4              -2.8 
Il8rb  Interleukin 8 receptor, beta        -2.3           -2.4           -2.0        2.8    
Xcr1  Chemokine (C motif) receptor 1              -2.7     -2.0     -2.7  -3.9 
-
15.3        -5.5  -2.4 
   < 2 fold increase/decrease 
   2-5 fold increase 
   6-20 fold increase 
   21-50 fold increase 
51-100 fold increase 
100+ fold increase 
   2 to 5 fold decrease  
6 to 20 fold decrease  
Figure 2 Chemokine Expression in the Brain and Spleen of F344 and HIV-1Tg Rats.
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Page 8 of 11in terms of pro-inflammatory cytokine production in the
spleen of the HIV-1Tg rats compared to the F344 rats.
The expression level of the pro-inflammatory cytokines,
IL-1a, IL-1b, and IFN-g, was 4- to 82-fold greater in the
spleen of the HIV-1Tg rats compared to the F344 rats
in both the single LPS exposure (SS+L) and ET (LL+L)
groups, indicating that the presence of viral proteins
may have an effect on innate immune responses. There
was also a difference in the expression of cytokine
receptors in the brain of the HIV-1Tg rats compared to
the F344 rats in response to LPS in both the ET state
and after a single exposure to LPS, suggesting that HIV-
1 viral proteins may interact with or work through cyto-
kine receptors in the brain. These data warrant further
investigation into the neuroimmune effects of HIV-1
viral proteins.
During ET, the production of pro-inflammatory cyto-
kines, such as IL-1b, IL-4, and IL-5, in response to LPS
(LL+L) was diminished in contrast to that elicited by a
single exposure to the endotoxin (SS+L). This altered
response was seen in the spleen and serum in both the
HIV-1Tg and F344 ET rats.
The spleen is an immune system organ, and, as such,
one would expect that a greater number of cytokine and
chemokine genes would be changed in the spleen in
response to an immune challenge compared to the
brain, and that is what we found in this study. In both
the HIV-1Tg and F344 rats, there was a greater
response to LPS in the spleen than in the brain.
Chemokines and their receptors have been implicated
in the neuropathogenesis of HIV-1 infection [62]. There
were significant differences in chemokine expression in
response to LPS in the HIV-1Tg rats compared to the
F344 rats. Enhanced levels of Ccl2 in HIV-1 patients
have been associated with HIV-1-associated dementia
[43]. Our results indicate that Ccl2 levels were increased
to a greater extent (3- to 5-fold) in the brain of the SS
+L and LL+L groups of HIV-1Tg rats versus the F344
rats, corroborating the role of upregulation of Ccl2 and
its implications on HIV encephalopathy. The levels of
the inflammatory CXC chemokines, Cxcl1, Cxcl2,
Cxcl10, and Cxcl11, were elevated to a greater extent
(0.1- to 40-fold) in the brain of the SS+L and LL+L
groups of the F344 rats compared to the HIV-1Tg rats.
Ccl2, Ccl7, and Ccl9, levels were increased to a greater
extent in the SS+L and LL+L groups of the spleen of
the HIV-1Tg rats in comparison to the F344 rats. Cxcl1
and Cxcl2 levels were elevated to a lesser extent in the
spleen of the SS+L and LL+L groups of the F344 rats
compared to the HIV-1Tg rats.
Chemokines and chemokine receptors define a net-
work throughout the body, playing critical roles in
immune and inflammatory responses as well as in many
pathological processes, in diseases such as multiple
sclerosis, Alzheimer’sd i s e a s e ,a n dH I V / A I D S[ 6 3 ] .
Cxcr4 and Ccr5 are reported to be co-receptors that
mediate HIV-1 entry [64]. In our study, the gene expres-
sion of the chemokine receptors, Ccr2, Ccr3, Ccr4, Ccr5,
Ccr7, Cxcr3, Ccr10, Ccr3, Cx3cr1, IL-8rb,a n dX c r 1 ,i n
the spleen of the ET group (LL+L) of F344 rats were
down-regulated, whereas those in the HIV-1Tg spleen
were not significantly different compared to the control
group (SS+S). All these receptors have been shown to
function as co-receptors for HIV-1infection in vitro [65],
which suggests that HIV-1 viral proteins may interact
with these chemokine receptors in vivo.T h e r ei sa l s o
evidence that chemokines and chemokine receptors play
an important part in the signaling of neuroprotective
effects in the brain [63].
In this study, we noted a distinct pattern of cytokine/
chemokine expression in the brain, spleen, and serum of
the HIV-1Tg and F344 rats in response to LPS, both
with and without ET. Identifying these distinct cytokine/
chemokine profiles may potentially be useful as indica-
tors of the onset and/or progression of certain disease
processes, such as sepsis. Further studies will be done to
determine the relationship of viral protein expression to
the production of cytokines and chemokines during ET.
Conclusions
T h ed a t af r o mo u rs t u d yp r o v i d eac o m p r e h e n s i v ep i c -
ture of the neuroimmune responses to infection during
ET, and strongly suggest that the presence of HIV-1
viral proteins may exacerbate those responses. These
findings also suggest the potential use of experimentally
defined cytokine/chemokine expression profiles as indi-
cators of altered immune function in various disease
states.
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